Smith & Nephew plc (SNN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Smith & Nephew plc (SNN) trades at $30.55 with AI Score 50/100 (Grade B). Smith & Nephew plc is a global medical technology company specializing in orthopedic reconstruction, sports medicine, and advanced wound management. Market cap: $12.91B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026SNN stock analysis for 2026: Analysts have set a consensus price target of $32.00 for Smith & Nephew plc, suggesting 4.7% upside from the current price of $30.55. The AI MoonshotScore is 50/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SNN: the 1 perspectives are evenly split.
How is this calculated? →Smith & Nephew plc (SNN) Healthcare & Pipeline Overview
Smith & Nephew plc (SNN) is a global medical device company focused on orthopedic reconstruction, sports medicine, and advanced wound management. With a diverse portfolio of innovative products and a presence in over 100 countries, SNN addresses critical needs in the healthcare sector, competing with major players in the medical device industry.
What Is the Investment Thesis for SNN?
Smith & Nephew presents a compelling investment thesis driven by its diversified product portfolio and global presence. The company's focus on high-growth segments within the medical device industry, such as sports medicine and advanced wound management, positions it for sustained revenue growth. With a market capitalization of $12.91B and a profit margin of 10.1%, SNN demonstrates financial stability. A dividend yield of 2.65% offers investors an income stream. Upcoming product launches and expansion into emerging markets could serve as catalysts for further growth. Potential risks include increasing competition and regulatory changes in the healthcare industry. The company's P/E ratio of 13.9 suggests a reasonable valuation relative to its earnings.
Based on FMP financials and quantitative analysis
SNN Key Highlights
- Market capitalization of $12.91B indicates a substantial and established company within the medical device industry.
- Profit margin of 10.1% demonstrates efficient operations and profitability in a competitive market.
- Gross margin of 68.0% reflects strong pricing power and efficient cost management in product manufacturing.
- Dividend yield of 2.65% provides an attractive income stream for investors, highlighting the company's commitment to shareholder returns.
- Beta of 0.74 suggests lower volatility compared to the overall market, indicating a relatively stable investment.
Who Are SNN's Competitors?
SNN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNC Centene Corporation | $65.62 | -3.30% | $32.40B | 73 |
| RPRX Royalty Pharma plc | $57.44 | -0.57% | $24.71B | 80 |
| HOLX Hologic, Inc. | $76.01 | +0.00% | $16.97B | 58 |
| NBIX Neurocrine Biosciences, Inc. | $174.54 | +0.16% | $17.55B | 94 |
| MEDP Medpace Holdings, Inc. | $557.60 | +2.58% | $15.92B | 95 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNN's Key Strengths?
- Diversified product portfolio across orthopedic reconstruction, sports medicine, and advanced wound management.
- Global presence with operations in over 100 countries.
- Strong brand reputation and established relationships with healthcare providers.
- Commitment to research and development, driving innovation in medical devices.
What Are SNN's Weaknesses?
- Exposure to currency fluctuations due to international operations.
- Dependence on regulatory approvals for new products.
- Intense competition from larger medical device companies.
- Potential for product liability claims.
What Could Drive SNN Stock Higher?
- New product launches in the orthopedic reconstruction and sports medicine segments are expected to drive revenue growth in the next 12-18 months.
- Expansion into emerging markets, particularly in Asia-Pacific, is expected to contribute to long-term growth.
- Continued investment in research and development is expected to lead to innovative medical devices and technologies.
- Potential acquisitions of smaller, innovative companies could expand the company's product portfolio and geographic reach.
What Are the Key Risks for SNN?
- Increasing competition from established and emerging medical device companies could put pressure on pricing and market share.
- Changes in healthcare regulations and reimbursement policies could negatively impact the company's profitability.
- Economic downturns could reduce healthcare spending and demand for medical devices.
- Product liability claims could result in significant financial losses and reputational damage.
- Currency fluctuations could negatively impact the company's financial results.
What Are the Growth Opportunities for SNN?
- Expansion in Emerging Markets: Smith & Nephew has a significant opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. The rising middle class and growing awareness of advanced medical treatments are driving demand for orthopedic reconstruction, sports medicine, and advanced wound management products. The emerging markets medical device market is projected to reach $200 billion by 2030, offering substantial growth potential for SNN.
- New Product Innovation: Smith & Nephew's commitment to research and development provides a strong foundation for new product innovation. The company can leverage its expertise in biomaterials, robotics, and digital technologies to develop next-generation medical devices that improve patient outcomes and reduce healthcare costs. The market for innovative medical devices is estimated at $150 billion annually, with significant opportunities for companies that can deliver breakthrough technologies.
- Strategic Acquisitions: Smith & Nephew can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Acquisitions of smaller, innovative companies can provide access to new markets and technologies, while larger acquisitions can enhance economies of scale and market share. The medical device industry is highly fragmented, with numerous potential acquisition targets.
- Digital Health Integration: Smith & Nephew can integrate digital health technologies into its products and services to enhance patient engagement, improve clinical outcomes, and reduce healthcare costs. The company can develop mobile apps, wearable sensors, and remote monitoring systems that provide real-time data to patients and healthcare providers. The digital health market is projected to reach $500 billion by 2025, offering significant opportunities for medical device companies.
- Advanced Wound Management: The global advanced wound care market is expected to reach $22 billion by 2027, driven by the increasing prevalence of chronic diseases such as diabetes and obesity. Smith & Nephew can capitalize on this trend by developing and marketing innovative wound care products that promote faster healing and reduce the risk of infection. The company's expertise in bioactive technologies and negative pressure wound therapy positions it well to capture a significant share of this growing market.
What Opportunities Does SNN Have?
- Expansion in emerging markets with growing healthcare spending.
- Development of new products and technologies to address unmet medical needs.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Integration of digital health technologies to enhance patient engagement and improve clinical outcomes.
What Threats Does SNN Face?
- Increasing competition from established and emerging medical device companies.
- Pricing pressures from healthcare providers and payers.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns that could reduce healthcare spending.
What Are SNN's Competitive Advantages?
- Strong brand reputation and established relationships with healthcare providers.
- Extensive portfolio of innovative medical devices and technologies.
- Global distribution network and presence in key markets.
- Significant investment in research and development.
- Regulatory expertise and compliance capabilities.
What Does SNN Do?
Founded in 1856 in Hull, England, Smith & Nephew began as a small pharmacy that evolved into a manufacturer of surgical dressings. Over the decades, the company expanded its product line and geographic reach through strategic acquisitions and organic growth. Today, Smith & Nephew plc is a global leader in medical technology, specializing in orthopedic reconstruction, sports medicine, and advanced wound management. The company's orthopedic reconstruction division offers a comprehensive range of hip and knee implants designed to improve patient outcomes and reduce recovery times. The sports medicine division provides innovative solutions for the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. Smith & Nephew's advanced wound management division develops and markets a wide range of products for the treatment and prevention of acute and chronic wounds, including leg ulcers, diabetic foot ulcers, and pressure ulcers. Headquartered in Watford, United Kingdom, Smith & Nephew serves healthcare providers in over 100 countries, with a strong presence in North America, Europe, and Asia-Pacific. The company's commitment to innovation and customer satisfaction has enabled it to maintain a leading position in the competitive medical device industry.
What Products and Services Does SNN Offer?
- Develops and manufactures orthopedic reconstruction implants for hip and knee replacement procedures.
- Offers sports medicine joint repair products for minimally invasive surgery of the joints.
- Provides trauma and extremities products for the stabilization of severe fractures.
- Supplies arthroscopic enabling technologies, including fluid management equipment and high-definition cameras.
- Offers advanced wound care products for the treatment and prevention of acute and chronic wounds.
- Provides advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration.
- Develops regenerative medicine products including skin, bone graft, and articular cartilage substitutes.
How Does SNN Make Money?
- Smith & Nephew generates revenue through the sale of medical devices and related products to healthcare providers.
- The company operates through a direct sales force and a network of distributors.
- Smith & Nephew invests heavily in research and development to create innovative products and maintain a competitive edge.
- The company focuses on building strong relationships with surgeons and other healthcare professionals to drive product adoption.
What Industry Does SNN Operate In?
Smith & Nephew operates in the global medical device industry, which is characterized by continuous innovation and increasing demand driven by an aging population and rising healthcare expenditures. The industry is highly competitive, with major players such as Johnson & Johnson, Stryker, and Zimmer Biomet. Smith & Nephew differentiates itself through its focus on specific segments, including sports medicine and advanced wound management. The global medical device market is projected to reach $600 billion by 2026, with a compound annual growth rate (CAGR) of approximately 5-7%.
Who Are SNN's Key Customers?
- Hospitals and surgical centers
- Orthopedic surgeons
- Sports medicine physicians
- Wound care specialists
- Healthcare providers in over 100 countries
FY2026 estForward Outlook
Wall Street analysts project Smith & Nephew plc revenue of about $6.57B for fiscal 2026, with EPS near $2.21. The estimate reflects 9 contributing analysts.
SNN Valuation & Market Position
With a $12.91B market cap, Smith & Nephew plc sits in the large-cap segment of the market. Relative to its peer group, SNN's quantitative score of 50/100 is below the peer average of 80/100.
ROE 12%Key Financial Metrics
Return on equity for Smith & Nephew plc stands at 11.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.1%, showing how much profit it generates from its asset base. SNN trades at a trailing price-to-earnings ratio of 13.94, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Smith & Nephew plc's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.09 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Smith & Nephew plc operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Watford, GB. The company is led by CEO Deepak S. Nath. SNN has traded publicly since 1999.
SNN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified product portfolio across orthopedic reconstruction, sports medicine, and advanced wound management.
- Global presence with operations in over 100 countries.
- Strong brand reputation and established relationships with healthcare providers.
- Commitment to research and development, driving innovation in medical devices.
Bear Case
- Exposure to currency fluctuations due to international operations.
- Dependence on regulatory approvals for new products.
- Intense competition from larger medical device companies.
- Potential for product liability claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SNN Latest News
-
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
seekingalpha.com · Jun 11, 2026
-
Smith & Nephew's robotics push wins surgeon backing
proactiveinvestors.co.uk · Jun 10, 2026
-
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
globenewswire.com · Jun 8, 2026
-
Bernstein Cuts PT on Smith & Nephew plc (SNN)
Yahoo! Finance: SNN News · May 26, 2026
SNN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNN.
Price Targets
Consensus target: $32.00
SNN MoonshotScore
What does this score mean?
The MoonshotScore rates SNN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
Smith & Nephew's robotics push wins surgeon backing
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Bernstein Cuts PT on Smith & Nephew plc (SNN)
Leadership: Deepak S. Nath
Chief Executive Officer
Deepak S. Nath is the Chief Executive Officer of Smith & Nephew plc. He brings extensive experience in the medical device industry, having previously held leadership positions at various global healthcare companies. His career spans over two decades, with a focus on driving innovation, commercial excellence, and operational efficiency. Nath's background includes a strong track record of successfully leading and transforming healthcare businesses. He is known for his strategic vision and commitment to improving patient outcomes.
Track Record: Since assuming the role of CEO, Deepak S. Nath has focused on accelerating Smith & Nephew's growth strategy, emphasizing innovation and market expansion. Key initiatives under his leadership include streamlining operations, enhancing the company's digital capabilities, and strengthening its presence in emerging markets. Nath has also prioritized sustainability and corporate social responsibility, aligning the company's business practices with environmental and social goals.
Smith & Nephew plc ADR Information
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. SNN, as an ADR, allows U.S. investors to invest in Smith & Nephew plc without the complexities of cross-border transactions. Each SNN ADR represents a specific number of ordinary shares of Smith & Nephew plc traded on its home market exchange.
- Home Market Ticker: London Stock Exchange (LSE), United Kingdom
What Investors Ask About Smith & Nephew plc (SNN) — Healthcare
What does Smith & Nephew plc do?
Smith & Nephew plc is a global medical technology company that develops, manufactures, and markets a wide range of medical devices and related products. The company operates in three main segments: orthopedic reconstruction, sports medicine, and advanced wound management. Its products are used by healthcare providers to treat patients with musculoskeletal conditions, sports injuries, and acute and chronic wounds. Smith & Nephew's commitment to innovation and customer satisfaction has enabled it to maintain a leading position in the competitive medical device industry.
What do analysts say about SNN stock?
Analyst consensus on SNN stock is mixed, with some analysts rating it as a "buy" or "outperform," while others rate it as a "hold" or "neutral." Key valuation metrics, such as the P/E ratio and dividend yield, are generally in line with industry averages. Growth considerations include the company's expansion in emerging markets, new product launches, and potential acquisitions. However, analysts also cite risks such as increasing competition, regulatory changes, and currency fluctuations. Investors should conduct their own due diligence and consider their individual investment objectives before making any investment decisions.
What are the main risks for SNN?
The main risks for Smith & Nephew plc include increasing competition from established and emerging medical device companies, which could put pressure on pricing and market share. Changes in healthcare regulations and reimbursement policies could negatively impact the company's profitability. Economic downturns could reduce healthcare spending and demand for medical devices. Product liability claims could result in significant financial losses and reputational damage. Currency fluctuations could negatively impact the company's financial results, given its global operations.
What are the key factors to evaluate for SNN?
Smith & Nephew plc (SNN) holds an AI score of 50/100 (moderate). P/E: 13.9x vs the S&P 500's ~20-25x. Analysts target $32.00 (+5%). Not financial advice.
How frequently does SNN data refresh on this page?
SNN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SNN's recent stock price performance?
Smith & Nephew plc (SNN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across orthopedic reconstruction, sports medicine, and advanced wound management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNN overvalued or undervalued right now?
Smith & Nephew plc (SNN) trades at 13.9x earnings. Analysts target $32.00 (+5%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SNN?
Before investing in Smith & Nephew plc (SNN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided in this dossier is based on publicly available sources and is intended for informational purposes only. It should not be construed as investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.